本帖最后由 老马 于 2013-3-13 13:43 编辑
5 `/ Q* `, o5 ?) \7 \; Y
# G% R+ L) u A8 U' r健择(吉西他滨)+顺铂+阿瓦斯汀, p1 a- N+ P9 k) C7 a9 Z
Gemzar +Cisplatin + Avastin
/ _$ o0 Z" Z8 y( @+ F8 Jhttp://annonc.oxfordjournals.org/content/21/9/1804.full: _# C: O- H# V. g; o8 y; h
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 8 ~7 N- ~6 V5 H/ i0 ^
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
3 I% t9 T, n% |- x( ^Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. & |, H7 I& T& I% S# d* ]
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 982)
# z5 m4 [: k4 X' t8 M7 d华为网盘附件:
\, _, O+ ?8 g7 R( a【华为网盘】ava.JPG
6 w7 N# I) v5 o! L' n: _; Y5 h1 Z |